Literature DB >> 23414537

Anti-IL-5 attenuates activation and surface density of β(2) -integrins on circulating eosinophils after segmental antigen challenge.

M W Johansson1, K A Gunderson, E A B Kelly, L C Denlinger, N N Jarjour, D F Mosher.   

Abstract

BACKGROUND: IL-5 activates α(M) β(2) integrin on blood eosinophils in vitro. Eosinophils in bronchoalveolar lavage (BAL) following segmental antigen challenge have activated β(2) -integrins.
OBJECTIVE: To identify roles for IL-5 in regulating human eosinophil integrins in vivo.
METHODS: Blood and BAL eosinophils were analysed by flow cytometry in ten subjects with allergic asthma who underwent a segmental antigen challenge protocol before and after anti-IL-5 administration.
RESULTS: Blood eosinophil reactivity with monoclonal antibody (mAb) KIM-127, which recognizes partially activated β(2) -integrins, was decreased after anti-IL-5. Before anti-IL-5, surface densities of blood eosinophil β(2) , α(M) and α(L) integrin subunits increased modestly post challenge. After anti-IL-5, such increases did not occur. Before or after anti-IL-5, surface densities of β(2) , α(M) , α(L) and α(D) and reactivity with KIM-127 and mAb CBRM1/5, which recognizes high-activity α(M) β(2) , were similarly high on BAL eosinophils 48 h post-challenge. Density and activation state of β(1) -integrins on blood and BAL eosinophils were not impacted by anti-IL-5, even though anti-IL-5 ablated a modest post-challenge increase on blood or BAL eosinophils of P-selectin glycoprotein ligand-1 (PSGL-1), a receptor for P-selectin that causes activation of β(1) -integrins. Forward scatter of blood eosinophils post-challenge was less heterogeneous and on the average decreased after anti-IL-5; however, anti-IL-5 had no effect on the decreased forward scatter of eosinophils in post-challenge BAL compared with eosinophils in blood. Blood eosinophil KIM-127 reactivity at the time of challenge correlated with the percentage of eosinophils in BAL post-challenge. CONCLUSION AND CLINICAL RELEVANCE: IL-5 supports a heterogeneous population of circulating eosinophils with partially activated β(2) -integrins and is responsible for up-regulation of β(2) -integrins and PSGL-1 on circulating eosinophils following segmental antigen challenge but has minimal effects on properties of eosinophils in BAL. Dampening of β(2) -integrin function of eosinophils in transit to inflamed airway may contribute to the decrease in lung inflammation caused by anti-IL-5.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23414537      PMCID: PMC3579563          DOI: 10.1111/j.1365-2222.2012.04065.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  65 in total

Review 1.  Linking integrin conformation to function.

Authors:  Janet A Askari; Patrick A Buckley; A Paul Mould; Martin J Humphries
Journal:  J Cell Sci       Date:  2009-01-15       Impact factor: 5.285

Review 2.  Eosinophils: biological properties and role in health and disease.

Authors:  Simon P Hogan; Helene F Rosenberg; Redwan Moqbel; Simon Phipps; Paul S Foster; Paige Lacy; A Barry Kay; Marc E Rothenberg
Journal:  Clin Exp Allergy       Date:  2008-04-01       Impact factor: 5.018

Review 3.  Leukocyte traffic in the lung.

Authors:  J C Hogg; C M Doerschuk
Journal:  Annu Rev Physiol       Date:  1995       Impact factor: 19.318

Review 4.  A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.

Authors:  William W Busse; Johannes Ring; Johannes Huss-Marp; Jean-Emmanuel Kahn
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

5.  Evidence that monoclonal antibodies directed against the integrin beta subunit plexin/semaphorin/integrin domain stimulate function by inducing receptor extension.

Authors:  A Paul Mould; Mark A Travis; Stephanie J Barton; Jennifer A Hamilton; Janet A Askari; Susan E Craig; Philip R Macdonald; Richard A Kammerer; Patrick A Buckley; Martin J Humphries
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

6.  Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor-induced adhesion molecule expression on eosinophils by p38 mitogen-activated protein kinase and nuclear factor-[kappa] B.

Authors:  Chun K Wong; Wai K Ip; Christopher W K Lam
Journal:  Am J Respir Cell Mol Biol       Date:  2003-02-14       Impact factor: 6.914

Review 7.  Eosinophil trafficking in allergy and asthma.

Authors:  Helene F Rosenberg; Simon Phipps; Paul S Foster
Journal:  J Allergy Clin Immunol       Date:  2007-05-03       Impact factor: 10.793

8.  Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events.

Authors:  M K Robinson; D Andrew; H Rosen; D Brown; S Ortlepp; P Stephens; E C Butcher
Journal:  J Immunol       Date:  1992-02-15       Impact factor: 5.422

Review 9.  Anti-integrin monoclonal antibodies.

Authors:  Adam Byron; Jonathan D Humphries; Janet A Askari; Sue E Craig; A Paul Mould; Martin J Humphries
Journal:  J Cell Sci       Date:  2009-11-15       Impact factor: 5.285

10.  Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits.

Authors:  I Dransfield; N Hogg
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

View more
  18 in total

1.  IL-3 Maintains Activation of the p90S6K/RPS6 Pathway and Increases Translation in Human Eosinophils.

Authors:  Stephane Esnault; Elizabeth A B Kelly; Zhong-Jian Shen; Mats W Johansson; James S Malter; Nizar N Jarjour
Journal:  J Immunol       Date:  2015-08-14       Impact factor: 5.422

Review 2.  Activation states of blood eosinophils in asthma.

Authors:  M W Johansson
Journal:  Clin Exp Allergy       Date:  2014-04       Impact factor: 5.018

3.  IL-3 up-regulates and activates human eosinophil CD32 and αMβ2 integrin causing degranulation.

Authors:  S Esnault; M W Johansson; E A Kelly; L Koenderman; D F Mosher; N N Jarjour
Journal:  Clin Exp Allergy       Date:  2017-01-23       Impact factor: 5.018

4.  Characterization of Siglec-8 Expression on Lavage Cells after Segmental Lung Allergen Challenge.

Authors:  Mats W Johansson; Elizabeth A Kelly; Christopher L Nguyen; Nizar N Jarjour; Bruce S Bochner
Journal:  Int Arch Allergy Immunol       Date:  2018-06-07       Impact factor: 2.749

5.  Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.

Authors:  Elizabeth A Kelly; Stephane Esnault; Lin Ying Liu; Michael D Evans; Mats W Johansson; Sameer Mathur; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

6.  Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort.

Authors:  Julia L M Dunn; Tetsuo Shoda; Julie M Caldwell; Ting Wen; Seema S Aceves; Margaret H Collins; Evan S Dellon; Gary W Falk; John Leung; Lisa J Martin; Paul Menard-Katcher; Amanda K Rudman-Spergel; Jonathan M Spergel; Joshua B Wechsler; Guang-Yu Yang; Glenn T Furuta; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

7.  Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating β2-integrin-dependent function in human eosinophils.

Authors:  Daniela J Carroll; Jeremy A O'Sullivan; David B Nix; Yun Cao; Michael Tiemeyer; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-09-06       Impact factor: 10.793

8.  α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin.

Authors:  Mats W Johansson; Douglas S Annis; Deane F Mosher
Journal:  Am J Respir Cell Mol Biol       Date:  2013-04       Impact factor: 6.914

9.  Integrin activation States and eosinophil recruitment in asthma.

Authors:  Mats W Johansson; Deane F Mosher
Journal:  Front Pharmacol       Date:  2013-04-01       Impact factor: 5.810

10.  Identification of genes expressed by human airway eosinophils after an in vivo allergen challenge.

Authors:  Stephane Esnault; Elizabeth A Kelly; Elizabeth A Schwantes; Lin Ying Liu; Larissa P DeLain; Jami A Hauer; Yury A Bochkov; Loren C Denlinger; James S Malter; Sameer K Mathur; Nizar N Jarjour
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.